Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides — Stella

Recruiting

Back to Cutaneous T Cell Lymphoma trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

University of Alabama at Birmingham, Birmingham, Alabama

Key details

Phase

Early testing

Sponsor

University of Alabama at Birmingham

Collaborators

Seagen Inc., Kyowa Kirin, Inc.

Enrollment target

~10 participants

Started

May 2023

Primary completion

April 2026

Age range

19 Years and older

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov